COMMISSION DECISION

of 14.6.2019

appointing an alternate member of the Pharmacovigilance Risk Assessment Committee
to represent healthcare professionals
COMMISSION DECISION

of 14.6.2019

appointing an alternate member of the Pharmacovigilance Risk Assessment Committee
to represent healthcare professionals

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency¹, and in particular Article 61a(1) thereof,

Whereas:

(1) Article 61a(1) of Regulation (EC) No 726/2004 requires that the Commission appoints representatives of healthcare professionals and patient organisations to the European Medicines Agency Pharmacovigilance Risk Assessment Committee.

(2) In accordance with Article 61a(1) of Regulation (EC) No 726/2004, a public call for expression of interest has been undertaken by the Commission. The European Parliament has been consulted on the results of the evaluation including the reserve list, for the applications, received in the framework of this call for expression of interest.

(3) By its decision of 25 February 2019, the Commission appointed members and alternates of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals and patient associations for a term of three years starting on 1 March 2019 and set up a reserve list by order of merit.

(4) Where a member or alternate representing healthcare professionals appointed by this decision is no longer capable of contributing efficiently to the work of the Committee, or resigns, the Commission may replace this member from the reserve list, for the remaining duration of the member’s mandate.

(5) Ms Ylva Böttiger resigned from her office and has to be replaced until the end of her term of office. It was Mr Roberto Frontini who confirmed his interest and availability from the reserve list.

HAS DECIDED AS FOLLOWS:

Article 1

Mr Roberto Frontini is hereby appointed as an alternate member of the Pharmacovigilance Risk Assessment Committee for the remaining period of the term finishing on 28 February 2022.

**Article 2**

This Decision shall take effect on the day of its adoption.

Done at Brussels, 14.6.2019

*For the Commission,*

*Vytenis ANDRIUKAITIS*

*Member of the Commission*